The effect of CYP3A5 enzyme genetic polymorphiism on atorvastatin modffying serum lipids
DENG Yong-ping
WANG Ruo-lun
CHEN Zhi-chao
Abstract：Objective To study the correlationship between CYP3A5 enzyme genetic polymorphism and effectivity as well as security of Atorvastatin to provide reference for clinical usage. Methods Forty-seven aged patients with hypercholesterolemia were enrolled. Atorvastatin(10 mg/d) was given for treatment. All patients' serum level of TC, TG, LDL-C, aminotransferase and phosphocreatine before and after the 24 weeks' treatment were tested. PCR-RELP technique was adopted to analyze CYP3A5 enzyme gene of the patients. Results There were 22 cases who were divided in the CYP3A5 1 group(including 2 cases for CYP3A5 1/1 and twenty for CYP3A5 1/ 3) and 25 into the CYP3 A5 3 group. After Atorvastatin treatment, both group showed reduction in serum level ofTC, LDL-C, TG(P＜0.05). The reduction amplitude of serum TC and LDL-C level of CYP3A5 3 group was (29.82 ± 5.25) % and (35.35 ± 4.06) % respectively, which was higher than that of CYP3A5 1 group [(19. 99 ± 3.16) % and (25.84 ± 2.31) %]. Conclusion CYP3A5 enzyme genetic polymorphism may influence Atorvastatin treatment.
Keywords：AtorvastatinCYP3A5Genetic polymorphismLipid regulation effect
Publication Date：2011-01-01
Online Publishing Date：2026-09-14(First online date of this platform, not the publication date of the document)